BioHarvest Sciences (NASDAQ:BHST) stated that full-year 2026 revenue guidance for its CDMO business has been narrowed to $4 million-$5 million, from $4 million-$6 million previously, while revenue guidance for the VINIA D2C business has been revised to $33 million-$35 million, from $38 million-$42 million previously.